News
-
HEALTH TECHNOLOGY ASSESSMENT | EU Implements New Rules to Offer Quicker Access to Advanced Medicines
The new rules establish an EU-wide framework for assessing health technologies by promoting collaboration and coordination among EU Member States. The goal is to help national authorities make more timely…
Read More » -
TIF CARE | A New Era in Healthcare Collaboration
Mark your Calendars for the TIF CARE Launch Currently, TIF Care is in its pilot phase and the official launch is scheduled for April 2025. We will continue to…
Read More » -
TIF READINESS ASSESSMENT TOOL | Is Your Country Ready for Advanced Thalassaemia Therapies?
In an era where medical advancements are progressing at an unprecedented rate, ensuring that these breakthroughs are accessible and appropriately integrated into national healthcare systems is a paramount challenge. This…
Read More » -
WEBINAR | New Advances in the Prevention of Thalassaemia: Potential for High-Prevalence Regions
📌 Webinar Title: New Advances in the Prevention of Thalassaemia: Potential for High-Prevalence Regions 📌 Date & Time: Tuesday, 21 January 2025 | 14:30-16:00 Athens Time, 19:30-21:00 Kuala Lumpur Time Webinar…
Read More » -
NEW FACTSHEET | The Advanced Therapy Medicinal Products (ATMPs) Labyrinth
Featuring comprehensive information on: The Regulation of ATMPs in the EU List of gene-based products approved by the EMA/FDA Challenges in Patient Access to ATMPs Key Recommendations for Improving Patient…
Read More » -
POSITION PAPER | The Views of TIF on Advanced Therapy Medicinal Products (ATMPs)
The Thalassaemia International Federation (TIF) is pleased to share its newly published Position Paper, titled “Advanced Therapy Medicinal Products (ATMPs).” This comprehensive document delves into the challenges eligible patients face…
Read More » -
INFOGRAPHICS | Mapping Blood Use in Patients with Thalassaemia Across the EU
Have You Ever Wondered How Much Blood is Consumed by Patients with Thalassaemia in EU Countries? To answer this question, the Thalassaemia International Federation (TIF) collected data from 15 EU…
Read More » -
EXCLUSIVE WEBINAR | Iron Load and the Importance of Reliable Monitoring in Haemoglobin Disorders
📌 Webinar Title: Iron Load and the Importance of Reliable Monitoring in Haemoglobin Disorders – The Transfusion Dependent Thalassaemia (TDT) Perspective 📌 Date & Time: 5 December 2024 / 13:30…
Read More » -
EDUCATIONAL WEBINAR FOR PATIENTS ON IRON OVERLOAD AND MONITORING | 21 November 2024
📌 Webinar Title: Webinar for Patients on Iron Overload and Iron Monitoring 📌 Date & Time: Thursday, November 21, 13:00 New York / 14:00 Rio de Janeiro This webinar…
Read More » -
SICKLE CELL DISEASE | FDA Grants Orphan Drug Designation to AND017
Announced by KIND Pharmaceuticals on October 25, 2024, ODD is granted to a drug or biological product to prevent, diagnose, or treat a rare disease or condition that affects fewer…
Read More »